<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H624AED72042B4CFDA90BA14272059F58" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 3491 IH: DeOndra Dixon INCLUDE Project Act of 2025</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3491</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250519">May 19, 2025</action-date><action-desc><sponsor name-id="D000197">Ms. DeGette</sponsor> (for herself, <cosponsor name-id="H001067">Mr. Hudson</cosponsor>, <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, <cosponsor name-id="C001053">Mr. Cole</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, and <cosponsor name-id="S001212">Mr. Stauber</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to carry out a program of research, training, and investigation related to Down syndrome, and for other purposes.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" style="OLC" id="H2FF30276E42345398724A8FD8526FB79"> 
<section id="HEBAF39B8C7934AEA9D85A8FBA099AEA5" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>DeOndra Dixon INCLUDE Project Act of 2025</short-title></quote>.</text></section> <section id="H5F3311D74B214A3BABE44518780FBD74"><enum>2.</enum><header>DeOndra Dixon INCLUDE Project</header><text display-inline="no-display-inline">Part B of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284 et seq.</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block id="HFCAD1AA294EC4AA88ADEA40BB0A9040D" style="OLC"> 
<section id="HEB389189DC1347FA9B1CF02716598704" commented="no"><enum>409K.</enum><header>Down syndrome research</header> 
<subsection id="H4E42494F81E44630A9E1DA54FE73B1DE" commented="no"><enum>(a)</enum><header>In general</header><text>The Director of NIH shall carry out a program of research, training, and investigation related to Down syndrome to be known as the <quote>INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE Project</quote> or the <quote>INCLUDE Project</quote>.</text></subsection> <subsection id="H06FC6684A5E64177B1F3AFFBB1DC9E73" commented="no"><enum>(b)</enum><header>Program elements</header><text>The program under subsection (a) shall include—</text> 
<paragraph id="H94E9FDA827524DBE8F77D532C68F73E5" commented="no"><enum>(1)</enum><text>high-risk, high-reward research on the effects of trisomy 21 on human development and health;</text></paragraph> <paragraph id="HC80C72272E224669BD5ED4554EEA5A48" commented="no"><enum>(2)</enum><text>promoting research for participants with Down syndrome across the lifespan, including cohort studies to facilitate improved understanding of Down syndrome and co-occurring conditions and development of new interventions;</text></paragraph> 
<paragraph id="H18AFCA65A96248BD97C9C222BDDD25F2" commented="no"><enum>(3)</enum><text>expanding the number of clinical trials that are inclusive of, or expressly for, participants with Down syndrome, including novel biomedical and pharmacological interventions and other therapies designed to promote or enhance activities of daily living;</text></paragraph> <paragraph id="H31A19805D153463299E646473C990897" commented="no"><enum>(4)</enum><text>research on the biological mechanisms in individuals with Down syndrome pertaining to structural, functional, and behavioral anomalies and dysfunction as well as stunted growth;</text></paragraph> 
<paragraph id="H67A5329367AF457E894D34558C0C7ECC" commented="no"><enum>(5)</enum><text>supporting research to improve diagnosis and treatment of conditions co-occurring with Down syndrome, including the identification of biomarkers related to risk factors, diagnosis, and clinical research and therapeutics;</text></paragraph> <paragraph id="HC47D3BF9834241CD9FD1C7CDA404E131" commented="no"><enum>(6)</enum><text>research on the causes of increased prevalence, and concurrent treatment, of co-occurring conditions, such as Alzheimer’s disease and related dementias and autoimmunity, in individuals with Down syndrome; and</text></paragraph> 
<paragraph id="H5754F9BF82614868A3BDD5184A8A561F" commented="no"><enum>(7)</enum><text display-inline="yes-display-inline">research, training, and investigation on improving the quality of life of individuals with Down syndrome and their families.</text></paragraph></subsection> <subsection id="H1D0630F7061C49729726795212DD05D5" commented="no"><enum>(c)</enum><header>Coordination; prioritizing nonduplicative research</header><text>The Director of NIH shall ensure that—</text> 
<paragraph id="HD6BD76D182EC4922BBD6573DEAFCC930" commented="no"><enum>(1)</enum><text>the programs and activities of the institutes and centers of the National Institutes of Health relating to Down syndrome and co-occurring conditions are coordinated, including through the Office of the Director of NIH and priority-setting reviews conducted pursuant to section 402(b)(3); and</text></paragraph> <paragraph id="HE04982EE5E864984865A0E751A372D0D" commented="no"><enum>(2)</enum><text>such institutes and centers, prioritize, as appropriate, Down syndrome research that does not duplicate existing research activities of the National Institutes of Health.</text></paragraph></subsection> 
<subsection id="H21CB8E84BB3A4A4D8D82A03923718D30" commented="no"><enum>(d)</enum><header>Consultation with stakeholders</header><text>In carrying out activities under this section, the Director of NIH shall, as appropriate and to the maximum extent feasible, consult with relevant stakeholders, including patient advocates, to ensure that such activities take into consideration the needs of individuals with Down syndrome.</text></subsection> <subsection id="H302BBDCCC81D4ADDAEA04F011A4654DA" commented="no"><enum>(e)</enum><header>Biennial reports to Congress</header> <paragraph id="HB62D2D9292E9496DBFB6A709CB85FE92" commented="no"><enum>(1)</enum><header>In general</header><text>The Director of NIH shall submit, on a biennial basis, to the Committee on Energy and Commerce and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the Senate, a report that catalogs the research conducted or supported under this section.</text></paragraph> 
<paragraph id="H27938A12F6F1409EA048CBB3EE3F6E6D" commented="no"><enum>(2)</enum><header>Contents</header><text>Each report under paragraph (1) shall include—</text> <subparagraph id="H0D71EC8AD8B343278F531321CB949C55" commented="no"><enum>(A)</enum><text>identification of the institute or center involved;</text></subparagraph> 
<subparagraph id="HADA3F6DDE1524FDBB8DB35146476FB2E" commented="no"><enum>(B)</enum><text>a statement of whether the research is or was being carried out directly by such institute or center or by multiple institutes and centers; and</text></subparagraph> <subparagraph id="HD246D7BEE3444FA6BBE6D9D53F4D1A04" commented="no"><enum>(C)</enum><text>identification of any resulting real-world evidence that is or may be used for clinical research and medical care for patients with Down syndrome.</text></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section> 
</legis-body></bill>

